Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 878,500 shares, a growth of 59.4% from the February 28th total of 551,300 shares. Based on an average daily volume of 1,770,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 13.7% of the company’s stock are short sold.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at approximately $40,000. Two Sigma Investments LP purchased a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at $66,000. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $72,000. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals in the 4th quarter worth about $162,000. Finally, Point72 Asset Management L.P. bought a new stake in Tonix Pharmaceuticals in the 4th quarter valued at about $526,000. Institutional investors own 82.26% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on TNXP shares. StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a “sell” rating for the company. Noble Financial reaffirmed an “outperform” rating and issued a $70.00 price target on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $20.17 on Friday. Tonix Pharmaceuticals has a one year low of $6.76 and a one year high of $672.00. The company has a market cap of $37.70 million, a P/E ratio of 0.00 and a beta of 2.23. The firm has a 50-day moving average of $18.79 and a 200-day moving average of $20.13. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million. Equities research analysts forecast that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.